Fundraising FoxSaccharo
Oakland, US · 1 known investors
Find your way into Saccharo
Sign up to see every warm intro you have to Saccharo
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Saccharo team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Saccharo is a biotech company developing antibody-drug conjugates and other therapeutics targeting dPSA (de-N-acetyl-polysialic acid), a tumor-specific glycan re-expressed on cancer cells, for the treatment of solid tumors and hematologic cancers. Its lead candidate, SAC-253, is a first-in-class ADC with potential broad oncology application, and it also develops diagnostic screening applications.
Founders & leadership
Investors · 1
Reported raises · per SEC filings
Form D private placements$7.4M disclosed across 1 round · 2022
▶$7.4MraisedSep 2023 · 45 investors · BiotechnologyRule 506(b)
▶$7.4MraisedSep 2023 · 45 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gregory R. Moe, Ph.D.Director
- Margaret KimExecutive Officer
- Sheryl A. Martin-Moe, Ph.D.Executive Officer, Director
- Winnie H. Wan, Ph.D.Director
- Offering amount
- $10.6M
- Amount sold
- $7.4M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Saccharo do?
- Saccharo is a biotech company developing antibody-drug conjugates and other therapeutics targeting dPSA (de-N-acetyl-polysialic acid), a tumor-specific glycan re-expressed on cancer cells, for the treatment of solid tumors and hematologic cancers. Its lead candidate, SAC-253, is a first-in-class ADC with potential broad oncology application, and it also develops diagnostic screening applications.
- Who founded Saccharo?
- Saccharo was founded by Sheryl Martin-Moe, Sherry Martin-Moe, Gregory Moe.
- Who are Saccharo's investors?
- Saccharo's investors include Sand Hill Angels.
- How much funding has Saccharo raised?
- Saccharo has disclosed $7.4M raised across 1 round.
- Where is Saccharo headquartered?
- Saccharo is headquartered in Oakland, US.